Archive for the ‘Pharmacology’ Category
Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study
Posted by: admin on: October 6, 2011
Previous studies have demonstrated that individual anti-hypertension medications have different effects when administered in the morning vs. the evening. However, the impact of administration timing on fixed combinations of anti-hypertensive medications on blood pressure control is still unknown. In the present study, we examined the administration time-dependent effects of a fixed combination of amlodipine and […]
FDA regulation, and off label use of atypical antipsychotic drugs
Posted by: admin on: October 6, 2011
Abilify, Seroquel, Zyprexa, Risperal – these are among the atypical antipsychotics for which Americans paid $10 billion in 2008. $6 billion of that was for off-label use. The FDA only approves drugs when their safety and efficacy have been tested for specific conditions. For example, an antipsychotic might be approved for the treatment of schizophrenia. […]
Evidence for Methotrexate as a Useful Treatment for Steroid-dependent Chronic Urticaria;
Posted by: admin on: October 5, 2011
Chronic urticaria is a relatively common disorder that can be severe and may impair quality of life. The management of recalcitrant chronic urticaria that is not responding to histamine antagonists includes short-term systemic corticosteroids, anti-inflammatory drugs (colchicine, dapsone and sulfasalazine) and immunomodulatory agents, such as cyclosporine, methotrexate, plasmapheresis and intravenous immunoglobulin.
Cell Phone Photos May Make Adherence a Snap
Posted by: admin on: September 22, 2011
Using a cell phone to snap and then send photos of each dose of medication right before taking it may improve treatment adherence in patients with methamphetamine addiction, new research shows. -Team@CMHF
FDA Approves New Drug for Hereditary Angioedema
Posted by: admin on: September 22, 2011
The US Food and Drug Administration (FDA) has approved icatibant subcutaneous injection (Firazyr) for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older. -Team@CMHF
Search
- drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
- rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
- nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards
